List of Tobi Podhaler drug patents

Tobi Podhaler is owned by Mylan Speciality Lp.

Tobi Podhaler contains Tobramycin.

Tobi Podhaler has a total of 11 drug patents out of which 3 drug patents have expired.

Expired drug patents of Tobi Podhaler are:

  • US7368102
  • US8715623
  • US9421166

Tobi Podhaler was authorised for market use on 22 March, 2013.

Tobi Podhaler is available in powder;inhalation dosage forms.

Tobi Podhaler can be used as treatment of cystic fibrosis patients with pseudomonas aeruginosa.

The generics of Tobi Podhaler are possible to be released after 04 November, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368102 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycosides
Dec, 2022

(a month ago)

US8715623 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(a month ago)

US9421166 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside
Dec, 2022

(a month ago)

US7516741 MYLAN SPECIALITY LP Aerosolization apparatus with feedback mechanism
Jan, 2024

(11 months from now)

USRE47526 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Apr, 2024

(1 year, 2 months from now)

US8069851 MYLAN SPECIALITY LP Aeorosolization apparatus with air inlet shield
Sep, 2024

(1 year, 7 months from now)

US11484671 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2024

(1 year, 9 months from now)

US8664187 MYLAN SPECIALITY LP Methods of treatment of endobronchial infections
Jun, 2025

(2 years from now)

US7559325 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Oct, 2025

(2 years from now)

US8869794 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncturing member
Sep, 2028

(5 years from now)

US10207066 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2030

(7 years from now)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 March, 2013

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic